Liva is delighted to introduce Michel Lussier as the new Chair of the Board as the business gears up to accelerate expansion to new markets.
LONDON, United Kingdom and COPENHAGEN, Denmark, August 30, 2023
Liva Healthcare has announced that it has appointed Michel Lussier as the new Chair of its Board to help take the company to its next level.
Michel is a successful business leader and entrepreneur specialising in medical technologies across the spectrum of cardiac rhythm management, interventional cardiology and digital therapeutics for diabetes management. Previously he had a long career at the global giant Medtronic focusing on innovation to tackle healthcare’s greatest challenges.
Michel Lussier, Chair of Liva , said “I am very proud to be taking on this role. Liva is a pioneer in digital therapeutics and their work is underpinned by the most rigorous clinical evidence. Liva has demonstrated the power of its behaviour change programmes to deliver impact at scale. At a time when health systems are struggling to cope with the increasing burden of obesity, type 2 diabetes and other cardiometabolic conditions, digital leaders like Liva are uniquely placed to support health systems shift to focus more on prevention rather than just treatment.”
Shahram Sharif, CEO of Liva, said “The Board is delighted to have appointed Michel as Chair. Michel has a distinguished track record and brings huge experience of innovation within the health sector. I’m looking forward to working together to accelerate the next stage of Liva’s growth and to advance adoption of digital therapeutics to help tackle the global burden of cardiometabolic disease.”
Rune Bech, Founder of Liva: “This is a pivotal time for the company as it embarks on the next stage of its investment and growth strategy and I am delighted we’ve found in Michel someone with the right combination of experience, skills and vision. We share a strong sense of purpose that by accelerating the adoption of digital therapeutics we can also empower patients to take greater control over their health and advance better outcomes for all.”
These changes come at a time when Liva is scaling up its partnership with the NHS after it was selected by the National Institute for Health and Care Excellence (NICE) as one of the leading digital therapeutics platforms to offer weight-loss programmes in combination with medication to NHS patients. NICE relied heavily on Liva’s extensive clinical evidence in drawing up the guidelines for these new measures to tackle the obesity crisis.
About Liva Healthcare
Liva is a leading digital therapeutics company that advances digital-first delivery of behaviour change programmes to improve health outcomes globally, at scale. Our team of dedicated healthcare professionals create personalised change programmes to support people in their journey to prevent, manage and treat obesity, type-2 diabetes and prediabetes and other cardiometabolic conditions.
The safety and efficacy of our digital therapeutic programmes are well-supported by extensive evidence from randomised controlled trials (RCTs) and other clinical studies. Liva’s innovative digital-first coaching platform integrates seamlessly into healthcare systems offering personalised clinical support to more than 50,000 patients.
Founded in Denmark, we have expanded our reach across multiple geographies, marking our presence as a global force for advancing better health outcomes. Our collaborations with healthcare systems, including the NHS, as well as partnerships with some of the world’s largest life science companies and health insurers allow us to impact lives on a large scale.
Liva is supported by a number of investors across Europe including MIG, Athos, Maj Invest, DHV and Verlinvest.
Media Enquiries – English
Sian Jarvis, CB, FRCGP(H)
Chief Marketing Officer
Mediekontakt – Dansk